Intratumoral phIL12 GET

Inclusion Criteria: * Histologically or cytologically confirmed, previously untreated cutaneous basal cell carcinoma located in head and neck region. * Solitary tumors, with largest diameter up to 3 cm, in the region where curative surgery is feasible. * Age 18-years or older. * Life expectancy \> 3 months. * Physical performance in accordance with the Karnofsky scale ≥ 70 or \< 2 in accordance with World Health Organization (WHO) scale. * The patient must be capable of understanding the treatment procedure and possible adverse events, which may arise during treatment. * The patient must be capable of signing the informed consent to participate in the clinical study (voluntary and conscientious consent after education). * Prior to inclusion in the trial, the patient must be presented at a multidisciplinary advisory team meeting. Exclusion Criteria: * Known malignancy elsewhere in/on the body. * Lesions not suitable for treatment with GET (invasion into the bone, infiltration of large vessels). * A life-threatening infection and/or severe heart failure and/or liver failure and/or other life-threatening systemic diseases. * Significantly reduced lung function, which requires the determination of DLCO. Patients should not be treated if DLCO is abnormal. * Treatment with immunosuppressive drugs, steroids and other drugs that would affect poor wound healing. * Age under 18-years. * Major disruptions in the coagulation system (who does not respond to the standard therapy - replacement of vitamin K or freshly frozen plasma). * A chronic decline in the kidney function (creatinine \> 150 µmol/L). * Epilepsy. * Pregnancy and breast-feeding. * The patient's incapability of comprehending the purpose or course of the trial, or not agreeing to be included in the trial. * Patients unwilling or unable to comply with the protocol requirements and scheduled visits.